Compare Lemonade Inc (LMND) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lemonade Inc vs Repligen Corporation Common Stock — how do they compare? Lemonade Inc trades at $43.21 (market cap $3.39B), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.31B). The key difference: Repligen Corporation Common Stock is far larger — about 3.3× Lemonade Inc's market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, Lemonade Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Lemonade Inc for 27 Days and Repligen Corporation Common Stock for 0 Days on average.
| LMND | RGEN | |
|---|---|---|
Market Cap | $3.39B | $11.31B |
Volume | 1,877,282 | 1,216,919 |
Sector | Financials | Health |
52-Week High | $96.57 | $194.57 |
52-Week Low | $43.86 | $102.87 |
Typical Hold Time | 27 Days | 0 Days |
Enterprise Value | $3.25B | $11.20B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lemonade (LMND) trades at $44.71, down 0.97% with bearish technical signals despite recent earnings beats. The company shows strong revenue growth from $257M in 2022 to $738M in 2025, though remains unprofitable with a -22.43% net margin. Analyst consensus is divided with a $67 price target, while technical indicators show oversold conditions with key support at $43.
Lemonade's path to profitability by late 2026 presents opportunity, but execution risks and persistent losses require caution. Expansion into new states and AI-driven efficiency improvements support growth, yet competitive pressures and cash flow challenges remain headwinds for investors seeking exposure to insurtech disruption.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lemonade Inc
Lemonade Inc operates in the insurance industry. The company offers digital and artificial intelligence based platform for various insurances and for settling claims and paying premiums. The platform ensures transparency in issuing policies and settling disputes.
Read more on LMND →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
